MARKED-UP VERSION OF AMENDMENTS

IN THE CLAIMS:

Claims 25-26 have been amended as follows:

25. (Twice Amended) A recombinant Avipox virus in which a DNA coding for the fusion protein according to claim 20 has been inserted, said DNA comprising a first DNA sequence isolated from Mycoplasma gallisepticum and coding for ~~an antigenic protein causing an antibody-antigen reaction with Mycoplasma gallisepticum immune serum or Mycoplasma gallisepticum infected serum~~ **the antigenic protein of claim 20**, and a second DNA sequence isolated from a Marek's disease virus gene coding for outer membrane protein gB**, said second DNA sequence coding for the signal polypeptide of claim 20**.

26. (Twice Amended) A recombinant live vaccine for anti-fowl Mycoplasma gallisepticum infection comprising as an effective ingredient a recombinant Avipox virus in which a DNA coding for the fusion protein according to claim 20 has been inserted, said DNA comprising a first DNA sequence isolated from Mycoplasma gallisepticum and coding for ~~an antigenic protein causing an antibody-antigen reaction with Mycoplasma gallisepticum immune serum or Mycoplasma gallisepticum infected serum~~ **the antigenic protein of claim 20**, and a second DNA sequence isolated from a Marek's disease virus gene coding for outer membrane protein gB**, said second DNA sequence coding for the signal polypeptide of claim 20**, wherein the fusion protein is capable, upon administration into a host cell, of immunizing that cell against subsequent infection with Mycoplasma gallisepticum.

REMARKS

By the present amendment, claims 25-26 have been amended to clarify the relationship between the first and second DNA sequences of claims 25-26 and (i) the antigenic protein of claim 20 and (ii) the signal polypeptide of claim 20, respectively.

Claims 20-26 are pending in the present application. Claims 20-24 are directed to a fusion protein, claim 25 is directed to a recombinant Avipox virus, and claim 26 is directed to a recombinant live vaccine.

Further to the remarks set forth in the response filed on March 18, 2002, the Applicants submit that support for claims 25-26 is found in particular in the paragraph bridging pages 4-5 (origin of the two DNA fragments of the hybrid DNA), the paragraph bridging pages 7-8 (DNA coding for antigenic Mg protein), the paragraph bridging pages 8-9 and the first full paragraph of page 9 (DNA coding for gB of MDV), the first paragraph of page 11 (recombinant Avipox virus), and the paragraph bridging pages 11-12 (recombinant live vaccine). Further, exemplification in particular as 40K-S of rFPV is found in the Examples of the present specification.

In the event this paper is not considered to be timely filed, the Applicants hereby petition for an appropriate extension of the response period. Please charge the fee for such extension and any other fees which may be required to our Deposit Account No. 01-2340.

Respectfully submitted,

ARMSTRONG, WESTERMAN & HATTORI, LLP

By: Nicolas Seckel

Nicolas E. Seckel
Attorney for Applicants
Reg. No. 44,373

Atty. Docket No. 981167

Suite 1000
1725 K Street, N.W.
Washington, D.C. 20006
Tel: (202) 659-2930
Fax: (202) 887-0357

NES:rep

Encl.: Request for Continued Examination
Petition for Two-Month Extension of Time